Risperidone Long-acting Injection (RLAI) – real world outcomes from the United Kingdom high-secure hospitals
作者: Simon GibbonEdward SilvaRupinder KalerInti QurashiMrigendra DasJon PatrickManjit GahirDouglas GrayLakshmanan RamachandranAnthony Maden
作者单位: 1Consultant Forensic Psychiatrist at St Andrews Healthcare, Northampton, UK
2Based at Ashworth Hospital, Mersey Care NHS Trust, Maghull, UK
3Based at Broadmoor Hospital, West London Mental Health Trust, Crowthorne, UK
4Based at The State Hospital, Carstairs, NHS Scotland, Carstairs, UK
5Consultant Forensic Psychiatrist at Rampton Hospital, Nottinghamshire Healthcare NHS Trust, Rampton, UK
刊名: The British Journal of Forensic Practice, 2011, Vol.13 (4), pp.264-269
来源数据库: Emerald Journal
DOI: 10.1108/14636641111190024
关键词: RisperidoneMentally disorder offendersAntipsychotic drugsDelayed-action preparationsMental illnessMedical treatment
原始语种摘要: Purpose(#br) – High-secure hospital patients often have complex presentations that are marked by co-morbidity, violence, histories of poor concordance with oral medication, and treatment resistance. The ability to give a long-acting medication with a low propensity for extra pyramidal side effects is of potential value to clinicians treating these patients. Risperidone Long-acting Injection (RLAI) is the first long-acting atypical antipsychotic medication and may be potentially useful in this population. This paper aims to investigate this issue. (#br)Design/methodology/approach(#br) – This was a retrospective, naturalistic study to investigate the use and effectiveness, using hard outcome measures, of RLAI in the four UK high-secure psychiatric hospitals. Hospital pharmacy databases at...
全文获取路径: Emerald  (合作)
分享到:

×